Oramed Pharmaceuticals Inc (Nasdaq/TASE: ORMP), a clinical-stage pharmaceutical company, has screened the first patients in its global Phase three trials of its oral insulin capsule ORMD-0801 intended for the treatment of type two diabetes, it was reported on Tuesday.
The patients were screened at United States sites participating in the company's ORA-D-013-1 trial, one of two Phase three trials being conducted in accordance with United States Food and Drug Administration (FDA) approved protocols.
Both Phase 3 trials, ORA-D-013-1 and ORA-D-013-2 are intended to treat type 2 diabetes patients who have inadequate glycaemic control over a period of 6 to 12 months. The double-blinded, placebo-controlled, multi-centre randomised trials are to hire a total of 1,125 patients to evaluate the efficacy and safety of the product. Efficacy data will be revealed after all patients have completed the first six-month treatment period.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults